necitumumab,osimertinib
nippon kayaku,astrazeneca,eli lilly
['osimertinib', 'necitumumab']
#asco22 multi-cohort study of osimertinib and necitumumab, a california cancer consortium study led by dr. jonathan riess covering various clinical scenarios. post osimertinib, addition of necitumumab (anti-egfr mab) showed rr 16%. some overlapping toxicity here. 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him